fbpx

Neurosense Therapeutics Ltd

NRSN

$1.02

Closing

▼-1.92%

1D

▲29.94%

YTD

NRSN

BBG0132WLC45

Exchange

Sector

Market cap

$21.12M

Volume

35,549

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$21.12M

Analysts' Rating

BUY

Price Target (Mean)

5.25

Total Analysts

2

P/E

Operating Margin

0.00%

Beta

Revenue Growth

0.00%

52 week high

$2.31

52 week low

$0.51

Div. Yield

%

EPS Growth

118.75

Company Profile

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer’s disease and Parkinson’s disease